Balaraman Kalyanaraman, PhD
Harry R. & Angeline E. Quadracci Professor in Parkinson’s Research
Visiting Fellow, Chemistry, Laboratory of Environmental Biophysics, National Institute of Environmental Sciences, Research Triangle Park, NC, 1978-1981
PhD, Chemistry, University of Alabama, Tuscaloosa, AL, 1978
MS, Chemistry, Indian Institute of Technology, Mumbai (formerly Bombay), India, 1972
BS, Chemistry, Loyola College, University of Madras, Chennai, India, 1970
I received my BS in chemistry from Loyola College, University of Madras in India, my MS in chemistry from the Indian Institute of Technology in India, and my PhD in chemistry from University of Alabama. I completed my postdoctoral training in chemistry at the Laboratory of Environmental Biophysics at the National Institute of Environmental Sciences. I came to MCW as a research associate at the National Biomedical EPR Center in 1984, and was appointed as MCW faculty in 1994. I served as director of the Biophysics Research Institute from 2000 to 2003, and as chair of the Department of Biophysics from 2003 to 2022. Also, I have served as an associate editor for Free Radicals in Biology and Medicine, Free Radical Research, and Biochemical Journal.
My research centers on understanding the role of oxidants, antioxidants, and mitochondrial therapeutics in cancer biology, immuno-oncology, cardio-oncology, and neurodegeneration.
My specific research areas are outlined below.
- Chemistry and Biophysics
- Detection of reactive oxygen and nitrogen species by EPR spin-trapping, fluorescence, optical stopped-flow, and HPLC techniques
- Syntheses of mitochondrially targeted spin traps, spin labels, and ROS-specific fluorescence probes
- EPR studies of mitochondria
- Mechanism of Signal Transduction/Cell Signaling
- Mitochondrial STAT3 and redox signaling
- Oxidant-induced iron signaling and apoptosis
- Chemotherapeutic drug (e.g., doxorubicin) toxicity and prevention; mechanism of apoptosis in tumor cells and normal cells
- Mechanism of Disease
- Role of mitochondria-derived oxidants in chemically induced Parkinsonism (e.g., MPTP, rotenone) in cell culture and animal models; mechanism of protein aggregation, proteosomal dysfunction, and apoptotic neuronal cell death
- Targeting of metabolism, bioenergetics, and redox signaling in cancer
- Development of new mitochondria-targeted antitumor and antiproliferative drugs
My research projects include the following:
Chemoprevention of Lung Cancer by Targeting Lonidamine to Mitochondria
The goal is to examine the efficacy and mechanism of a novel mitochondrial targeting agent (Mito-LON) in treating lung cancer and brain metastasis.
- Chemoprevention of Lung Cancer with Mitochondria-targeted Honokiol
The goal is to evaluate the chemopreventive potential of Mito-HNK, a mitochondria-targeted compound, using both in vitro and in vivo models of lung adenocarcinoma (LUAD) and determine its mechanism of action, to determine its efficacy for inhibiting LUAD progression and metastasis and its suitability for human clinical trials.
Gang Cheng, Research Assistant Professor
(Cheng G, Karoui H, Hardy M, Kalyanaraman B.) Free Radic Biol Med. 2023 Aug 20;205:175-187 PMID: 37321281 SCOPUS ID: 2-s2.0-85162228734 06/16/2023
(Cheng G, Hardy M, Kalyanaraman B.) Sci Rep. 2023 May 04;13(1):7254 PMID: 37142668 PMCID: PMC10160116 SCOPUS ID: 2-s2.0-85158068757 05/05/2023
(Cheng G, Karoui H, Hardy M, Kalyanaraman B.) Cancers (Basel). 2023 Feb 08;15(4) PMID: 36831432 PMCID: PMC9953882 02/26/2023
(Kalyanaraman B, Cheng G, Hardy M, You M.) Expert Opin Ther Targets. 2023;27(10):939-952 PMID: 37736880 SCOPUS ID: 2-s2.0-85173986031 09/22/2023
(Kalyanaraman B.) Redox Biol. 2022 Nov;57:102497 PMID: 36242913 PMCID: PMC9563555 SCOPUS ID: 2-s2.0-85139734287 10/16/2022
(Murphy MP, Bayir H, Belousov V, Chang CJ, Davies KJA, Davies MJ, Dick TP, Finkel T, Forman HJ, Janssen-Heininger Y, Gems D, Kagan VE, Kalyanaraman B, Larsson NG, Milne GL, Nyström T, Poulsen HE, Radi R, Van Remmen H, Schumacker PT, Thornalley PJ, Toyokuni S, Winterbourn CC, Yin H, Halliwell B.) Nat Metab. 2022 Jun;4(6):651-662 PMID: 35760871 PMCID: PMC9711940 SCOPUS ID: 2-s2.0-85132951828 06/28/2022
(Zhang Q, Xiong D, Pan J, Wang Y, Hardy M, Kalyanaraman B, You M.) Cancers (Basel). 2022 May 21;14(10) PMID: 35626143 PMCID: PMC9140024 SCOPUS ID: 2-s2.0-85130231561 05/29/2022
(Huang M, Xiong D, Pan J, Zhang Q, Wang Y, Myers CR, Johnson BD, Hardy M, Kalyanaraman B, You M.) Adv Sci (Weinh). 2022 Apr;9(12):e2101267 PMID: 35243806 PMCID: PMC9036031 SCOPUS ID: 2-s2.0-85125564839 03/05/2022
(Kalyanaraman B.) FASEB J. 2022 Apr;36(4):e22226 PMID: 35233843 PMCID: PMC9242412 SCOPUS ID: 2-s2.0-85125582482 03/03/2022
(Cheng G, Hardy M, You M, Kalyanaraman B.) Sci Rep. 2022 Mar 24;12(1):5143 PMID: 35332210 PMCID: PMC8948292 SCOPUS ID: 2-s2.0-85127039662 03/26/2022
(Michalski R, Smulik-Izydorczyk R, Pięta J, Rola M, Artelska A, Pierzchała K, Zielonka J, Kalyanaraman B, Sikora AB.) Front Chem. 2022;10:930657 PMID: 35864868 PMCID: PMC9294461 07/23/2022
(Kalyanaraman B, Cheng G, Hardy M.) Front Oncol. 2022;12:816504 PMID: 35756631 PMCID: PMC9214210 SCOPUS ID: 2-s2.0-85133350425 06/28/2022